AN2 Therapeutics, a clinical-stage company developing novel therapies for rare infectious diseases, has secured $40 million in a private placement financing round. The company plans to use these funds to advance its lead drug candidate, AN2690, through late-stage clinical trials for the treatment of onychomycosis. Specific investors were not detailed in the announcement.